Background
==========

Children with acute leukemia have been treated with the combination of chemotherapy and prophylactic cranial irradiation. This combination therapy was found to improve their prognoses dramatically \[[@B1]\]. However, long after the irradiation exposure, some survivors developed secondary intracranial tumors such as glioma, sarcoma, and meningioma \[[@B1],[@B2]\]. In this paper, we report a patient who developed multiple intracranial meningiomas, all of which had aggressive clinical features and high MIB-1 labeling indices, 25 years after prophylactic cranial irradiation to treat acute leukemia in childhood. Radiation-induced meningiomas (RIMs) with multiple lesions, all of which have high MIB-1 labeling indices, have not been reported yet. The correlation between the clinical features of RIMs and the MIB-1 labeling index are discussed, along with a review of the literature.

Case presentation
=================

A 28-year-old woman presented with a 1-week history of headache, nausea, and vomiting. The patient had a medical record of acute lymphoblastic leukemia at 3 years of age. She had received a chemotherapy regimen that comprised vincristine, methotrexate, L-asparaginase, cytosine arabinoside, and 6-mercaptopurine, as well as whole-brain irradiation at a total dose of 18 Gy. The combined treatment brought the patient into clinical remission, and the patient was followed up until she was 18 years old with no relapse of the disease. Thereafter, she was lost from oncologic follow up. Six months before her visit to our hospital, she consulted another doctor about a mild head injury. Computed tomography (CT) of the brain showed no traumatic findings but incidentally revealed a small lesion in the left frontal convexity (Figure [1](#F1){ref-type="fig"}). Six months later, she suffered from headache, nausea, and vomiting. A further CT examination revealed rapid enlargement of the lesion, and she was referred to our institution. Magnetic resonance imaging (MRI) of the brain revealed two other small-mass lesions in the right middle and frontal fossae (Figure [2](#F2){ref-type="fig"}). Surgical resection of the left frontal-mass lesion was performed. During surgery, the tumor was found to adhere to the dura mater of the left frontal convexity and the wall of the superior sagittal sinus. The tumor was extensively removed, and the dural attachment was cauterized (Simpson grade 2). Histopathological examination revealed frequent mitoses, hypercellularity, and focal necrosis in the tumor specimens. Immunohistochemical analysis revealed an MIB-1 labeling index of approximately 20%. The pathological diagnosis was atypical meningioma.

![**Preoperative axial computed tomography (CT) and fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI). (A)** CT image showing a tumor approximately 1.5 cm in diameter in the left frontal convexity (arrow). (**B)** Tumor in the left frontal convexity. The tumor mass and perifocal edema caused a shift of the brain to the right side. (**C)** Tumor in the right middle cranial fossa. (**D)** Right frontal base tumor (cranial fossa) and the tumor in the left frontal convexity.](1477-7819-12-123-1){#F1}

![**Histological findings.** The left-frontal meningioma tissue shows hypercellular lesions **(A)**, with focal necrosis **(B)** (original magnification, ×100), and a whorl formation **(C**) (original magnification, ×100). Frequent mitoses **(D)** (original magnification, ×200) are also evident. The immunohistochemical profile revealed approximately 20% Ki-67-positivity **(E)** (original magnification, ×100).](1477-7819-12-123-2){#F2}

Postoperatively, the patient presented with neither neurological deficits nor radiological evidence of recurrence at the surgical site. Six months after surgery, a follow-up brain MRI revealed enlargement of the right middle fossa lesion. Thus, the two lesions on the right side were resected. Histopathological examination identified both tumors as meningothelial meningioma with MIB-1 labeling indices of approximately 10% and 15%, respectively. The postoperative clinical course was uneventful, and the patient developed no neurological deficits. Nine months after the first surgery, a follow-up MRI revealed a tumor recurrence in the left parasagittal region. Twelve months after the first surgery, a follow-up MRI identified a recurrence of the left frontal convexity meningioma in the frontal superior sagittal sinus and the frontal convexity dura matter. During the third operation, the tumor was found to have invaded into the frontal superior sagittal sinus, where it had attached to the bridging vein. The tumor was resected extensively and the dural attachment was cauterized. After surgery, the patient developed no neurological deficits.

Discussion
==========

Since Mann *et al*. reported the first case of RIM in 1953 \[[@B3]\], more than 750 cases have been reported in the English-language literature. Several features that distinguish between RIM and sporadic meningioma (SM) have been indicated. SM is known as a benign tumor that accounts for approximately 20% of all intracranial tumors. SM tends to occur during middle age and has a female predominance \[[@B4]-[@B6]\]. Benign meningioma accounts for 90% of SM cases. Atypical meningioma and anaplastic meningioma each account for 5% and 3% of SM cases, respectively \[[@B7]\]. Roser *et al*. analyzed 600 cases of SMs and revealed that 91% of SMs are classified as World Health Organization (WHO) grade 1, with a mean MIB-1 labeling index of 3.28%. Additionally, 7% and 2% of SM cases are classified as WHO grade 2 (mean MIB-1 labeling index, 9.95%) and grade 3 (mean MIB-1 labeling index, 12.18%), respectively \[[@B8]\].

RIM tends to occur in patients who are younger at the time of clinical presentation \[[@B9]\] and has an increased incidence of multiplicity. Strojan *et al*. reported 126 secondary meningiomas, 10 (8%) of which had multiple lesions \[[@B10]\]. Another report estimated that nearly 16% of RIM cases have multiple mass lesions \[[@B11]\] and a higher rate of atypical or aggressive forms. Al-Mefty *et al*. reported that approximately 31% of RIM cases were atypical meningiomas with a higher recurrence rate \[[@B12]\], which was also suggested by several other investigators \[[@B13],[@B14]\]. A pathological study of RIMs revealed that RIMs presented with more malignant features than SMs, namely, hypercellularity, pleomorphism, increased mitotic figures, and necrotic changes \[[@B15],[@B16]\].

Immunohistochemical analysis is also useful for evaluating the malignant potential and recurrence rate of SMs \[[@B17]\]. The proliferative marker, MIB-1 labeling index, is a useful method for this purpose. However, several reports state that the MIB-1 labeling index is not an appropriate method with which to evaluate the malignant potential and recurrence rate of RIMs \[[@B12],[@B18]\]. All of the lesions in our RIM case had high MIB-1 labeling indices, and the tumor recurred postoperatively within 1 year. Thus, we reviewed the literature that evaluated the MIB-1 labeling index for RIMs.

From the literature, the MIB-1 labeling indices of 27 tumors from 21 patients were examined (Table [1](#T1){ref-type="table"}) \[[@B10],[@B12],[@B18]-[@B20]\]. Among these, 12 recurrent tumors had higher MIB-1 labeling indices than the MIB-1 labeling indices of the non-recurrent tumors (mean ± SD); recurrent tumors versus non-recurrent tumors, 9.1 ± 5.1 versus 4.9 ± 3.9, *P* \<0.05). Eighteen tumors were classified as WHO grade 1, with a mean MIB-1 labeling index of 4.66%, and four tumors were grade 2 (17.4%) with a mean MIB-1 labeling index of 14.25%. Among the 21 RIM cases, 11 had multiple lesions and 8 cases developed recurrence (72.7%). RIM cases with multiple lesions had higher MIB-1 labeling indices than the MIB-1 labeling indices of those with single lesions (mean ± SD; multiple lesion tumors versus single lesion tumors, 8.6 ± 5.2 versus 3.6 ± 1.8, *P* \<0.01). Collectively, these data show that the MIB-1 labeling index is as important for predicting the recurrence of RIMs, as it is for predicting the recurrence of SM. Noticeably, the pathological features of RIMs with multiple lesions are not always consistent. The growth rate of each lesion varies \[[@B15],[@B16],[@B19]\], and some lesions are managed conservatively \[[@B2],[@B10],[@B11]\]. RIM should be treated more aggressively than SM because of its greater malignant potential. Undoubtedly, surgical resection is the first choice of treatment. For RIM located in surgically inaccessible regions, including the skull base or around the brain stem, radiosurgery, including gamma knife surgery, is another treatment option \[[@B21],[@B22]\].

###### 

Summary of reported cases of radiation-induced meningioma

  **Case**                      **Age (years)/sex**           **Histology**                **Cranial irradiation TD**         **Age (years), latency**   **WHO grade/histology**                **Recurrence**                                             **Multiple**   **Ki-67 (%)**   **Author name, year**
  ----------------------------- ----------------------------- ---------------------------- ---------------------------------- -------------------------- -------------------------------------- ---------------------------------------------------------- -------------- --------------- -----------------------
  1                             1/M                           Cerebellar medulloblastoma   30 Gy to WB, 10.5 Gy to tumor      12, 11                     1                                      CR 12 years                                                No             1.8             S.Nishio 1998
  2                             2/M                           ALL                          24 Gy to WB                        16, 14.5                   1                                      CR 3 years                                                 No             3.7             S.Nishio 1998
  3                             23/F                          Astrocytoma                  60 Gy to humor                     37, 14                     1                                      Progression of the primary disease, dead after 22 months   No             1.7             S.Nishio 1998
  4                             17/F                          Ependymoma                   30 Gy to WB and 30 Gy to tumor     38, 21                     1                                      CR 3 years                                                 No             6.9             S.Nishio 1998
  5                             10/F                          Medulloblastoma              30 Gy to WB and 29.5 Gy to tumor   41.5, 31.5                 Benign, transitional                   No                                                         No             1               P.Strojan 2000
  6                             11/M                          Medulloblastoma              31.5 Gy to WB and 24 Gy to tumor   35, 24                     Benign, meningotheliomatous            No                                                         Yes (3)        9               P.Strojan 2000
  Benign, transitional          3                                                                                                                                                                                                                                                         
  ?                             ?                                                                                                                                                                                                                                                         
  7                             9/F                           ALL                          10 Gy to WB                        29, 20.5                   Benign, transitional                   Yes (3)                                                    Yes (3)        2               P.Strojan 2000
  13.5                          ALL, relapse                  24 Gy to WB                  30, 21.5                           Atypical, transitional     7                                                                                                                                
  31, 22.5                      Atypical, transitional        15                                                                                                                                                                                                                          
  31.5, 23                      ?                             ?                                                                                                                                                                                                                           
  8                             4/M                           ALL                          18 Gy to WB                        13, 9.5                    Atypical, fibrous                      Yes (1)                                                    Yes (2)        15              P.Strojan 2000
  14.5, 11                      Benign, fibrous               1                                                                                                                                                                                                                           
  18.5, 15                      ?                             ?                                                                                                                                                                                                                           
  9                             3/M                           NHL                          19.5 Gy to basal skull             15.5, 12.5                 Atypical, fibrous                      No                                                         No             3               P.Strojan 2000
  3.5                           NHL, relapse                  24 Gy to basal skull                                                                                                                                                                                                        
  10                            13/M                          Craniopharyngiom             HD Gy to tumor                     44, 31                     Atypical                               No                                                         Yes (3)        ?               Al-Mefty 2004
  47, 34                        Benign, meningotheliomatous   1                                                                                                                                                                                                                           
  53, 41                        ?                             ?                                                                                                                                                                                                                           
  11                            12/M                          NHL                          HD Gy to WB                        34, 22                     Benign, meningotheliomatous            Yes (1)                                                    Yes (2)        3               Al-Mefty 2004
  37, 25                        ?                             ?                                                                                                                                                                                                                           
  12                            3/M                           Medulloblastom               HD (50 Gy)                         9, 6                       Clear cell                             Yes (1)                                                    Yes (NA)       7               Samer KE, 2012
  13                            7/F                           AML                          MD (16 Gy)                         14, 7                      Meningothelial, chordoid               Yes (1)                                                    Yes (NA)       10              Samer KE, 2012
  14                            5/M                           Ependymoma                   HD (55)                            18, 13                     Meningothelial                         Yes (1)                                                    No             6               Samer KE, 2012
  15                            7/M                           ALL                          MD (14 Gy)                         16, 9                      Fibroblastic                           No                                                         No             4               Samer KE, 2012
  16                            2/M                           Medulloblastoma              HD (50 Gy)                         13, 11                     Atypical meningotherial, xanthomatou   Yes (1)                                                    Yes (NA)       6.2             Samer KE, 2012
  17                            7/F                           ALL                          HD (30 Gy)                         17, 10                     Meningothelial, chordoid               Yes (2)                                                    Yes (NA)       7.2             Samer KE, 2012
  18                            4/F                           Medulloblastoma              HD (50 Gy)                         17, 13                     Meningothelial, fibroblastic           No                                                         Yes (2)        6.9             Samer KE, 2012
  19                            5/M                           Ependymoma                   HD (55 Gy)                         17, 12                     Atypical meningothelial, rhabdoid      Yes (1)                                                    Yes (NA)       10.4            Samer KE, 2012
  20                            2/M                           Ependymoma                   HD (55 Gy)                         10, 8                      Xanthomatous                           No                                                         No             5               R.Ijiri 2000
  21                            3/M                           ALL                          18 Gy to WB                        28, 25                     Benign, meningotheliomatous            Yes (1)                                                    Yes (3)        10              Current case report
  Benign, meningotheliomatous   15                                                                                                                                                                                                                                                        
  Atypical                      20                                                                                                                                                                                                                                                        

WB, whole brain; CR, complete remission; ?, no surgical treatment and unknown pathological features; HD, high dose (greater than 20 Gy); M, male; F, female; ALL, acute lymphoblastic leukemia; NHL, non-hodgkin lymphoma; AML, acute myelogenous lymphoma; TD, total dose; NA, not available.

Conclusion
==========

We experienced a case of multiple RIMs with rapid tumor progression and recurrence within a short period, and the MIB-1 labeling indices in all tumors exceeded 10%. The MIB-1 labeling index is an important index for evaluating the malignant potential and recurrence of both RIMs and SMs. RIMs have a greater malignant potential than SMs, and thus, a more aggressive treatment is required for RIMs.

Consent
=======

We explained to the patient and family about the RIMs and written informed consent was obtained from them for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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